Table 1.
Characteristics of the population
| Total (n = 48) | Ticagrelor (n = 24) | Clopidogrel (n = 24) | |
|---|---|---|---|
| Evaluation upon arrival at InCor | |||
| Age, years [median (p25–p75)] | 56.5 (51.0–64.5) | 61 (54.5–67.0) | 55 (48.5–63.5) |
| Male sex, n (%) | 29 (60.4%) | 14 (58.3%) | 10 (41.6%) |
| Body mass index, kg/m2 [mean (± SD)] | 26.8 (± 4.6) | 26.9 (± 4.5) | 26.8 (± 4.7) |
| Hypertension, n (%) | 24 (50%) | 12 (50%) | 12 (50%) |
| Type II diabetes, n (%) | 11 (22.9%) | 6 (25%) | 5 (20.8%) |
| Dyslipidemia, n (%) | 16 (33.3%) | 10 (41.6%) | 6 (25%) |
| Smoking, n (%) | 38 (79.1%) | 19 (79.1%) | 19 (79.1%) |
| Family history for CAD, n (%) | 9 (18.7%) | 6 (25%) | 3 (12.5%) |
| Chronic kidney disease (ClCr < 60 ml/min), n (%) | 2 (4.1%) | 2 (8.3%) | 0 |
| Previous myocardial infarction | 0 | 0 | 0 |
| Time from symptom onset to fibrinolysis, in mins [median (p25–p75)] | 180 (120–255) | 200 (150–290) | 160 (95–207.5) |
| Time from symptom onset to arrival at CCU, in days [median (p25–p75)] | 1.6 (0.7–2.7) | 1.5 (0.5–2.8) | 1.6 (0.8–2.7) |
| Time from symptom onset to PCI, in days [median (p25–p75)] | 2.4 (1.4–3.6) | 2.5 (1.2–4.0) | 2.3 (1.7–3.5) |
| Time from symptom onset to MCE, in days [median (p25–p75)] | 4.7 (3.6–6.2) | 5.1 (4.0–6.2) | 4.5 (3.0–5.6) |
| Anterior MI, n (%) | 22 (45.8%) | 8 (33.3%) | 14 (58.3%) |
| Killip 1, n (%) | 45 (93.7%) | 21 (87.5%) | 24 (100%) |
| Killip 2, n (%) | 3 (6.2%) | 3 (12.5%) | 0 |
| TIMI risk score—low, n (%) | 31 (64.5%) | 15 (62.5%) | 16 (66.6%) |
| TIMI risk score—moderate, n (%) | 16 (33.3%) | 8 (33.3%) | 8 (33.3%) |
| TIMI risk score—high, n (%) | 1 (2%) | 1 (4.1%) | 0 |
| Use of clopidogrel before randomization in TREAT trial, n (%) | 26 (54.1%) | 13 (54.1%) | 13 (54.1%) |
| Variables obtained during hospitalization at InCor | |||
| Hemodynamic data | |||
| Culprit coronary artery | |||
| Anterior descending artery, n (%) | 22 (45.8%) | 9 (37.5%) | 13 (54.1%) |
| Circumflex artery, n (%) | 6 (12.5%) | 4 (16.6%) | 2 (8.3%) |
| Right coronary artery, n (%) | 20 (41.6%) | 11 (45.8%) | 9 (37.5%) |
| Rescue angioplasty, n (%) | 5 (10.4%) | 2 (8.3%) | 3 (12.5%) |
| Percutaneous coronary intervention, n (%) | 41 (85.4%) | 22 (91.6%) | 19 (79.1%) |
| Exclusive clinical treatment | 7 (14.5%) | 2 (8.3%) | 5 (20.8%) |
| Residual lesion in non-culprit arteries, n (%) | 20 (41.6%) | 13 (54.1%) | 7 (29.1%) |
| Medications used during hospitalization | |||
| Acetylsalicylic acid, n (%) | 48 (100%) | 24 (100%) | 24 (100%) |
| Enoxaparin, n (%) | 48 (100%) | 24 (100%) | 24 (100%) |
| Statin, n (%) | 48 (100%) | 24 (100%) | 24 (100%) |
| Angiotensin-converting enzyme inhibitor, n (%) | 47 (97.9%) | 24 (100%) | 23 (95.8%) |
| Beta-blocker, n (%) | 44 (91.6%) | 22 (91.6%) | 22 (91.6%) |
| Morphine, n (%) | 13 (27%) | 6 (25%) | 7 (29.1%) |
| Proton pump inhibitor, n (%) | 10 (20.8%) | 6 (25%) | 4 (16.6%) |
| Ranitidine, n (%)† | 43 (89.5%)† | 19 (79.1%)† | 24 (100%)† |
| Laboratory data | |||
| Leukocytes, per mm3 [mean (± SD)] | 10,525 (± 2932) | 10,519 (± 2519) | 10,530 (± 3351) |
| Platelet count, µL [mean (± SD)] | 223,208 (± 61,633) | 218,500 (± 58,410) | 227,916 (± 65,608) |
| Average platelet volume, fL [median (p25–p75)] | 11 (10.3–11.6) | 11.1 (10.4–11.7) | 10.9 (10.3–11.6) |
| Creatinine, mg/dL [median (p25–p75)] | 0.8 (0.7–1.0) | 0.8 (0.7–1.0) | 0.8 (0.7–1.0) |
| Glycated hemoglobin,% [median (p25–p75)] | 5.8 (5.4–6.0) | 5.8 (5.4–6.1) | 5.7 (5.5–5.9) |
| Blood glucose, mg/dL [median (p25–p75)] | 105 (97–122) | 118 (100–128) | 102 (94–110) |
| C-reactive protein, mg/L [median (p25–p75)] | 18 (5–38.1) | 18.5 (4.6–46.3) | 17.1 (5.3–31.9) |
| Interleukin-6 [median (p25–p75)] | 4.4 (1.7–7.2) | 4.2 (2.2–8.1) | 4.4 (1.5–7.2) |
| Natriuretic peptide type B, pg/mL [median (p25–p75)] | 128 (88–215) | 170 (88–286) | 118 (88–180) |
| Troponin, ng/mL [median (p25–p75)] | 29.6 (10.5–50) | 38.8 (14.4–50) | 24.0 (8.5–46.9) |
| CKMB-mass, ng/mL [median (p25–p75)] | 17.4 (4.4–58.9) | 18.6 (3.3–108.6) | 15.6 (5.9–41.9) |
| Total cholesterol, mg/dL [mean (± SD)] | 198 (± 51) | 207 (± 55) | 189 (± 46) |
| LDL-cholesterol, mg/dL [mean (± SD)] | 125 (± 42) | 131 (± 41) | 119 (± 42) |
| HDL-cholesterol, mg/dL [mean (± SD)] | 41 (± 10) | 42 (± 12) | 41 (± 8) |
| Triglycerides, mg/dL [median (p25–p75)] | 133 (90–185) | 132 (92–185) | 141 (90–191) |
CCU coronary care unit, PCI percutaneous coronary intervention, MCE myocardial contrast echocardiography
†p = 0.018. There were no statistically significant differences between the other groups